Company / Return on Equity (ROE)
PALVELLA THERAPEUTICS, INC. Return on Equity (ROE) History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-27.9%
FY2024
5-year range
-120.0% / -27.9%
FY2020-FY2024
Trend
-
vs FY2023
Sector context
#89 of 190
Health Care
What the data says
PALVELLA THERAPEUTICS, INC. reports negative total equity of -27.9% in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-27.9% in FY2024 with a 5-year CAGR of +21.7%.
Improved from -49.6% to -27.9% over the past 4 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +92.1pp
- 5-Year Change
- +21.7pp
- 10-Year Change
- -
Sector benchmark
#89 of 190 in Health CareTop 47% of 190This company -27.9% Sector average -50.4%
▼
+44.8% above sector average
Key checks
Key Insights
- Currently 22.6pp above the Health Care sector average.
- Lowest return on equity (roe) in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 1.15 (distress zone, below 1.8 threshold)
- Strong profit margin: 43.7%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -27.9% | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | -120.0% | -141.9% |
| FY2020 | -49.6% | +0.0% |
| FY2019 | -49.6% | +67.6% |
| FY2018 | -153.2% | -69.5% |
| FY2017 | -90.4% | +0.0% |
| FY2016 | -90.4% | -100.1% |
| FY2015 | -45.2% | +17.4% |
As of FY2024 · SEC 10-K Annual Filings · Updated Jun 30, 2026